10 research outputs found
Pengaruh Komunikasi Terapeutik Perawat Terhadap Kepuasan Pasien Di Rawat Jalan RSUD Jogja
The Objective of this study is to know influence of nurse therapeutic communication to satisfaction of patients satisfaction in RSUD Yogyakarta. The study was a quantitative research methods such as surveys of descriptive inferential research with cross sectional approach. Number of samples in this research is 285 sample in inpatient and 140 in emergency room. The instrument used a questionnaire. Analysis of data using multiple linear regression. This study show that there is the influence of therapeutic communication nurse to satisfaction of outpatients and Emergency room in RSUD Yogyakarta, and orientation phase is a phase that most influence on patient satisfaction. The most influential to therapeutic communication is termination stage
Frequency of CD4+CD161+ T Cell and Interleukin-10 Expression in Inflammatory Bowel Diseases
Enhancement of Cancer Vaccine Therapy by Systemic Delivery of a Tumor-Targeting Salmonella-
Recombinant Modified Vaccinia Virus Ankara (MVA) Expressing Wild-Type Human p53 Induces Specific Antitumor CTL Expansion
Neutrophil-to-Lymphocyte Ratio and Intratumoral CD45RO-Positive T Cells as Predictive Factors for Longer Survival of Patients with Colorectal Liver Metastasis after Hepatectomy
A phase II study of novel three peptides combination with gemcitabine as a first-line therapy for advanced pancreatic cancer (VENUS-PC study).
High expression of olfactomedin-4 is correlated with chemoresistance and poor prognosis in pancreatic cancer.
Pancreatic cancer has an extremely poor prognosis, and identification of novel predictors of therapeutic efficacy and prognosis is urgently needed. Chemoresistance-related molecules are correlated with poor prognosis and may be effective targets for cancer treatment. Here, we aimed to identify novel molecules correlated with chemoresistance and poor prognosis in pancreatic cancer. We established 10 patient-derived xenograft (PDX) lines from patients with pancreatic cancer and performed next-generation sequencing (NGS) of tumor tissues from PDXs after treatment with standard drugs. We established a gene-transferred tumor cell line to express chemoresistance-related molecules and analyzed the chemoresistance of the established cell line against standard drugs. Finally, we performed immunohistochemical (IHC) analysis of chemoresistance-related molecules using 80 pancreatic cancer tissues. From NGS analysis, we identified olfactomedin-4 (OLFM4) as having high expression in the PDX group treated with anticancer drugs. In IHC analysis, OLFM4 expression was also high in PDXs administered anticancer drugs compared with that in untreated PDXs. Chemoresistance was observed by in vitro analysis of tumor cell lines with forced expression of OLFM4. In an assessment of tissue specimens from 80 patients with pancreatic cancer, Kaplan-Meier analysis showed that patients in the low OLFM4 expression group had a better survival rate than patients in the high OLFM4 expression group. Additionally, multivariate analysis showed that high expression of OLFM4 was an independent prognostic factor predicting poor outcomes. Overall, our study revealed that high expression of OLFM4 was involved in chemoresistance and was an independent prognostic factor in pancreatic cancer. OLFM4 may be a candidate therapeutic target in pancreatic cancer
Additional file 4: Figure S3. of Predictive biomarkers for the efficacy of peptide vaccine treatment: based on the results of a phase II study on advanced pancreatic cancer
Frequency of CD4+ CD45RA- CD25high cells and CD11b + CD33+ cells. (a), (c) There were no differences in the percentages of CD4+ CD45RA- CD25high cells and CD11b + CD33+ cells in the 46 patients before and after treatment. (b), (e) Before and after treatment, there were no differences in the percentages of CD4+ CD45RA- CD25high cells and CD11b + CD33+ cells between the patients with a long survival (n = 6) and the patients with a short survival (n = 19) in the HLA-A*2402-matched group. (c), (f) Before and after treatment, there were no differences in the percentages of CD4+ CD45RA- CD25high cells and CD11b + CD33+ cells between the patients with a long survival (n = 6) and the patients with a short survival (n = 15) in the HLA-A*2402-unmatched group. (TIF 60 kb
Additional file 2: Table S1. of Predictive biomarkers for the efficacy of peptide vaccine treatment: based on the results of a phase II study on advanced pancreatic cancer
Comparison of prognostic factors according to the numbers of peptide-specific responses (n = 36 HLA-A*2402-matched patients). (DOCX 28 kb